Stock News

$0.43 EPS Expected for Universal Forest Products, Inc. (UFPI); 4 Analysts Are Bullish Amphastar Pharmaceuticals, Inc. (AMPH) Last Week

Analysts expect Universal Forest Products, Inc. (NASDAQ:UFPI) to report $0.43 EPS on February, 28.They anticipate $0.09 EPS change or 26.47% from last quarter’s $0.34 EPS. UFPI’s profit would be $26.31 million giving it 20.64 P/E if the $0.43 EPS is correct. After having $0.55 EPS previously, Universal Forest Products, Inc.’s analysts see -21.82% EPS growth. The stock increased 0.91% or $0.32 during the last trading session, reaching $35.5. About 18,446 shares traded. Universal Forest Products, Inc. (NASDAQ:UFPI) has risen 12.86% since February 14, 2017 and is uptrending. It has underperformed by 3.84% the S&P500.

Among 6 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Amphastar Pharmaceuticals had 26 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, October 27 by Jefferies. BMO Capital Markets maintained the shares of AMPH in report on Friday, November 10 with “Market Perform” rating. Jefferies maintained Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) rating on Thursday, November 9. Jefferies has “Buy” rating and $23.0 target. The stock of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has “Buy” rating given on Monday, August 10 by Zacks. Raymond James downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) on Tuesday, March 14 to “Outperform” rating. Piper Jaffray maintained Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) rating on Tuesday, January 30. Piper Jaffray has “Buy” rating and $26.0 target. The stock of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has “Buy” rating given on Wednesday, August 9 by Piper Jaffray. BMO Capital Markets maintained Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) on Thursday, October 26 with “Hold” rating. The firm has “Buy” rating by Jefferies given on Friday, August 11. The firm earned “Hold” rating on Thursday, November 9 by Raymond James. See Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) latest ratings:

30/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Maintain
01/12/2017 Broker: Needham Rating: Buy New Target: $23.0 Maintain
09/11/2017 Broker: Jefferies Rating: Buy New Target: $23.0 Maintain
10/11/2017 Broker: BMO Capital Markets Rating: Market Perform Old Target: $16 New Target: $17 Maintain
09/11/2017 Broker: Raymond James Rating: Hold Downgrade
27/10/2017 Broker: Jefferies Rating: Buy New Target: $19.0 Maintain
26/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $16.0 Maintain
20/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $19.0 Maintain
26/09/2017 Broker: Needham Rating: Buy New Target: $20.0 Maintain
15/09/2017 Broker: Needham Rating: Buy New Target: $18.0 Maintain

The stock decreased 0.43% or $0.08 during the last trading session, reaching $18.33. About 3,005 shares traded. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has risen 8.19% since February 14, 2017 and is uptrending. It has underperformed by 8.51% the S&P500.

Investors sentiment increased to 0.91 in Q3 2017. Its up 0.15, from 0.76 in 2017Q2. It improved, as 11 investors sold Amphastar Pharmaceuticals, Inc. shares while 32 reduced holdings. 10 funds opened positions while 29 raised stakes. 20.04 million shares or 0.68% less from 20.18 million shares in 2017Q2 were reported. Cadence Management Limited Liability Corp holds 22,903 shares or 0.03% of its portfolio. Blackrock Inc has 5.51M shares. Dekabank Deutsche Girozentrale has 0% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Jpmorgan Chase invested in 393,375 shares or 0% of the stock. 28,000 are owned by State Of Wisconsin Board. The Massachusetts-based Boston Advisors has invested 0.02% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Winslow Evans And Crocker has invested 0.01% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). National Bank Of Montreal Can reported 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). California State Teachers Retirement Sys has invested 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Barclays Public Ltd holds 842 shares. Qs Investors Lc reported 79,683 shares stake. Argent Cap Mngmt Ltd Co reported 121,275 shares or 0.08% of all its holdings. Swiss Bank reported 0% stake. Citigroup holds 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) or 188,910 shares. State Street Corporation has 0% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH).

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has market cap of $842.74 million. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. It currently has negative earnings. The companyÂ’s product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

Among 2 analysts covering Universal Forest Products (NASDAQ:UFPI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Universal Forest Products had 6 analyst reports since October 16, 2015 according to SRatingsIntel. The firm has “Neutral” rating by DA Davidson given on Friday, October 16. The stock of Universal Forest Products, Inc. (NASDAQ:UFPI) has “Hold” rating given on Tuesday, October 17 by BMO Capital Markets. The firm has “Underperform” rating given on Tuesday, December 8 by DA Davidson. The company was upgraded on Thursday, October 20 by DA Davidson. The company was upgraded on Tuesday, January 12 by DA Davidson.

Investors sentiment decreased to 1.09 in Q3 2017. Its down 0.17, from 1.26 in 2017Q2. It dived, as 25 investors sold Universal Forest Products, Inc. shares while 52 reduced holdings. 27 funds opened positions while 57 raised stakes. 16.27 million shares or 0.09% more from 16.25 million shares in 2017Q2 were reported. North Point Managers Oh invested in 2,600 shares. Nationwide Fund Advisors, Pennsylvania-based fund reported 29,668 shares. Thrivent For Lutherans accumulated 12,450 shares. Ftb Advsrs accumulated 333 shares. Bnp Paribas Arbitrage Sa has invested 0.01% in Universal Forest Products, Inc. (NASDAQ:UFPI). Price T Rowe Inc Md owns 547,689 shares. Envestnet Asset Mngmt accumulated 3,077 shares or 0% of the stock. Ameriprise Inc owns 167,484 shares. Invesco Ltd holds 0% of its portfolio in Universal Forest Products, Inc. (NASDAQ:UFPI) for 50,843 shares. Virginia Retirement Et Al holds 8,500 shares or 0.01% of its portfolio. 670,612 were accumulated by Franklin Res. Renaissance Tech Ltd owns 72,203 shares. State Teachers Retirement Systems stated it has 0.01% in Universal Forest Products, Inc. (NASDAQ:UFPI). Pcj Counsel Limited reported 0.06% stake. Blackrock owns 3.19 million shares.

Since September 12, 2017, it had 0 insider purchases, and 8 selling transactions for $2.26 million activity. On Tuesday, October 31 the insider COLEMAN ROBERT D sold $456,765. 3,000 shares were sold by GREENE CHARLES SCOTT, worth $114,165 on Monday, December 11. $743,880 worth of Universal Forest Products, Inc. (NASDAQ:UFPI) shares were sold by MISSAD MATTHEW J. The insider WEBSTER PATRICK M sold 996 shares worth $88,575. 500 shares were sold by COLE MICHAEL R, worth $55,000 on Thursday, October 26.

Leave a Reply

Your email address will not be published. Required fields are marked *